



Consumer Alert

April 12, 2007

Topic: FDA Advises Discontinuation of Sales and Marketing of Pergolide® for the Treatment of Parkinson's Disease

Recently, the U.S. Food and Drug Administration (FDA) asked manufacturers of the Parkinson's drug, Pergolide®, to discontinue sales and marketing of the drug. This request was made after two new studies showed that patients with Parkinson's disease who were treated with Pergolide®, had an increased chance of serious damage to their heart valves when compared to patients who did not receive the drug.

The effect of this voluntary withdrawal on supplies of Pergolide®, currently in pharmacies will not be immediate. This delay will allow time for healthcare professionals and patients to discuss appropriate treatment options and to change treatments.

More information about this Public Health Advisory can be found on FDA's website at: <http://www.fda.gov/cder/drug/advisory/tegaserod.htm>

If you have any questions regarding the information in this announcement, please contact your GBS Customer Service Representative at (410) 832-1333 or (800) 337-4973.